Assessing Efficacy of Haemophilus influenzae type b Combination Vaccines

Regulatory approval of diphtheria and tetanus toxoids and acellular pertussis (DTaP)-based combination vaccines containing Haemophilus influenzae type b (Hib) has been delayed in the United States because of difficulty in assessing the effect of lower Hib immunogenicity on vaccine efficacy compared with the immunogenicity of the specific Hib component administered separately. Hib conjugate vaccines confer protection by eliciting serum anticapsular antibody and priming for immunologic memory. Therefore, compelling proof of efficacy would be demonstration that a combination vaccine primes for memory and elicits antibody responses that are not inferior to those elicited by other US-licensed Hib conjugate vaccines, not necessarily the specific Hib component used in the combination. Vaccinated infants also can be considered protected if their serum anticapsular antibody concentrations are > or =0.15 microg/mL immediately before the booster dose given in the second year of life, when antibody concentrations are lowest. These alternative serologic approaches offer a strong scientific and regulatory rationale for licensure of effective DTaP-based Hib combination vaccines. This article was published in Clinical Infectious Diseases.

Author: Granoff DM

Published: 2001

» Visit web page (English)

(Located at

Citation: Granoff DM. Assessing Efficacy of Haemophilus influenzae type b Combination Vaccines. Clinical Infectious Diseases. 2001;33(Suppl. 4):S278-S287.

Resource types: Peer-reviewed journal

Diseases/vaccines: Haemophilus influenzae type b (Hib)

Topics: Disease/vaccine specific information

Regions: North America and Europe